Main Article Content

Muhammad Idrees
Muhammad Tariq Masood Khan
Waleed Bawazir
Mohannad S. Hazzazi
Saeed M. Kabrah
Malik A. Altayar
Soad Al- Jaouni
Majed N. Almashjary
Steve Harakeh
Yasar M Yousafzai


β-Thalassemia, prevalence, thalidomide, efficacy, safety


Background: β-thalassemia is an autosomal recessive hereditary hemoglobin production disorder characterized by abnormal hemoglobin synthesis. The efficient and safe therapies for transfusion-dependent β-thalassemia (TDT) patients are desperately required to minimize the requirement for blood transfusion.

Objective: To establish the safety and efficacy of low-dose thalidomide in TDT patients.

Methodology: The retrospective cohort study was conducted in Khyber Medical University, Peshawar and Blood Diseases Clinic, Peshawar to investigate the safety and efficacy of low-dose thalidomide therapy in TDT patients. Samples were collected from the diagnosed cases of TDT patients whose ages were ≥3 years and were on thalidomide treatment for a period of ≥6 months. Complete blood count CBC was performed on Sysmex XP-100, Japan and biochemical tests were performed on Cobas 6000 analyzer series. Comprehensive patients’ demographics, clinical history and prognosis data were recorded and analyzed using the SPPS 27.

Results: The patient characteristics, biochemical parameters and hematological response were assessed and statistically tested for 384 TDT patients using low-dose thalidomide therapy. Applying the criteria for the Hb level achievement, we marked the significant results (<0.001) for Excellent, Good, and Partial responders that were 184 (47.9%), 96 (25%), and 60 (15.6%), respectively. The common side effects observed with the drug included abdominal discomfort, nausea, vomiting, headache, constipation, dizziness, fatigue, anxiety, repeated infections, and skin rash, that were controlled with symptomatic treatment and/or dose adjustment.

Conclusion: Collectively, thalidomide is safe and effective in increasing Hb levels thus reducing the requirements of blood transfusion in TDT patients. Future clinical trials are suggested to strengthen the efficacy and safety of low-dose thalidomide and to establish clinical guidelines for its rational use in TDT patients.


Abstract 122 | pdf Downloads 33


1. Galanello R, Perseu L, Satta S, Demartis F, Campus S. Phenotype-genotype correlation in β-thalassemia. Thalassemia reports. 2011;1(1):16-20.
2. Kukongviriyapan V, Somparn N, Senggunprai L, Prawan A, Kukongviriyapan U, Jetsrisuparb A. Endothelial dysfunction and oxidant status in pediatric patients with hemoglobin E-β thalassemia. Pediatric cardiology. 2008;29(1):130-5.
3. Hamed EM, Meabed MH, Aly UF, Hussein RRS. Recent Progress in Gene Therapy and Other Targeted Therapeutic Approaches for Beta Thalassemia. Curr Drug Targets. 2019;20(16):1603-23.
4. Rachmilewitz EA, Giardina PJ. How I treat thalassemia. Blood, The Journal of the American Society of Hematology. 2011;118(13):3479-88.
5. Oliveros O, Trachtenberg F, Haines D, Gerstenberger E, Martin M, Carson S, et al. Pain over time and its effects on life in thalassemia. American journal of hematology. 2013;88(11):939-43.
6. Kattamis A, Forni GL, Aydinok Y, Viprakasit V. Changing patterns in the epidemiology of β‐thalassemia. European Journal of Haematology. 2020;105(6):692-703.
7. Biswas B, Naskar NN, Basu K, Dasgupta A, Basu R, Paul B. Transfusion-transmitted infections, its risk factors and impact on quality of life: An epidemiological study among β-thalassemia major children. Asian Journal of Transfusion Science. 2022;16(1):99.
9. Barbarossa A, Iacopetta D, Sinicropi MS, Franchini C, Carocci A. Recent advances in the development of thalidomide-related compounds as anticancer drugs. Current Medicinal Chemistry. 2022;29(1):19-40.
10. Noordermeer D, de Laat W. Joining the loops: β‐Globin gene regulation. IUBMB life. 2008;60(12):824-33.
11. Chandra J, Parakh N, Sidharth, Singh N, Sharma S, Goel M, Pemde H. Efficacy and safety of thalidomide in patients with transfusion-dependent thalassemia. Indian Pediatrics. 2021;58(7):611-6.
12. Chen J-M, Zhu W-J, Liu J, Wang G-Z, Chen X-Q, Tan Y, et al. Safety and efficacy of thalidomide in patients with transfusion-dependent β-thalassemia: a randomized clinical trial. Signal Transduction and Targeted Therapy. 2021;6(1):405.
13. Jain M, Chakrabarti P, Dolai TK, Ghosh P, Mandal PK, Baul SN, De R. Comparison of efficacy and safety of thalidomide vs hydroxyurea in patients with Hb E-β thalassemia-a pilot study from a tertiary care Centre of India. Blood Cells, Molecules, and Diseases. 2021;88:102544.
14. Li X, Hu S, Liu Y, Huang J, Hong W, Xu L, et al. Efficacy of thalidomide treatment in children with transfusion dependent β-thalassemia: A retrospective clinical study. Frontiers in Pharmacology. 2021;12:722502.
15. Lu Y, Wei Z, Yang G, Lai Y, Liu R. Investigating the Efficacy and Safety of Thalidomide for Treating Patients With ß-Thalassemia: A Meta-Analysis. Frontiers in Pharmacology. 2022;12:814302.
16. Cappellini MD, Porter JB, Viprakasit V, Taher AT. A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies? Blood reviews. 2018;32(4):300-11.
17. Nag A, Radhakrishnan VS, Kumar J, Bhave S, Mishra DK, Nair R, Chandy M. Thalidomide in patients with transfusion-dependent E-beta thalassemia refractory to hydroxyurea: a single-center experience. Indian Journal of Hematology and Blood Transfusion. 2020;36:399-402.
18. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, et al. Identification of a primary target of thalidomide teratogenicity. science. 2010;327(5971):1345-50.
19. Donovan KA, An J, Nowak RP, Yuan JC, Fink EC, Berry BC, et al. Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. Elife. 2018;7:e38430.
20. Costa BA, Mouhieddine TH, Richter J. What’s Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma. Targeted Oncology. 2022;17(4):383-405.
21. Yamamoto J, Ito T, Yamaguchi Y, Handa H. Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders. Chemical Society Reviews. 2022.
22. Li Y, Cai W, Jin F, Wang X, Liu W, Li T, et al. Thalidomide alleviates pulmonary fibrosis induced by silica in mice by inhibiting ER stress and the TLR4-NF-κB pathway. International Journal of Molecular Sciences. 2022;23(10):5656.
23. Chen J, Zhu W, Cai N, Bu S, Li J, Huang L. Thalidomide induces haematologic responses in patients with β‐thalassaemia. European Journal of Haematology. 2017;99(5):437-41.
24. Kalra M, Khanna VK, Trehan A, Mahajan A. Thalidomide in transfusion dependent thalassemia: hope or hype. Journal of Pediatric Hematology/Oncology. 2017;39(6):485.
25. Li Y, Ren Q, Zhou Y, Li P, Lin W, Yin X. Thalidomide has a significant effect in patients with thalassemia intermedia. Hematology. 2018;23(1):50-4.
26. Ren Q, Zhou Y-L, Wang L, Chen Y-S, Ma Y-N, Li P-P, Yin X-L. Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermedia. Annals of hematology. 2018;97:1933-9.
27. Jain M, De R, Jitani A, Chakrabarti P, Mondal P, Baul S. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian J Hematol Blood Transfus. 2019;35(1):S54.
28. Yang K, Wu Y, Zhou Y, Long B, Lu Q, Zhou T, et al. Thalidomide for patients with β-thalassemia: a multicenter experience. Mediterranean journal of hematology and infectious diseases. 2020;12(1).
29. Ansari SH, Ansari I, Wasim M, Sattar A, Khawaja S, Zohaib M, et al. Evaluation of the combination therapy of hydroxyurea and thalidomide in β-thalassemia. Blood Advances. 2022;6(24):6162-8.
30. Yassin AK. Promising response to thalidomide in symptomatic β-thalassemia. Indian Journal of Hematology and Blood Transfusion. 2020;36(2):337-41.